Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout

Also in ALS news: QurAlis obtains rights to Lilly compounds

Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B round that will allow it to move forward with a clinical plan that also includes Alzheimer’s disease.

Existing investor Morningside Ventures led the round. Amylyx Pharmaceuticals Inc. CFO Jeffrey Trigilio told BioCentury more than 15 other investors,

Read the full 645 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers